These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 24204156)

  • 21. Visit-to-visit variability of lipid measurements as predictors of cardiovascular events.
    Waters DD; Bangalore S; Fayyad R; DeMicco DA; Laskey R; Melamed S; Barter PJ
    J Clin Lipidol; 2018; 12(2):356-366. PubMed ID: 29310989
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SGLT2-inhibition increases total, LDL, and HDL cholesterol and lowers triglycerides: Meta-analyses of 60 randomized trials, overall and by dose, ethnicity, and drug type.
    Bechmann LE; Emanuelsson F; Nordestgaard BG; Benn M
    Atherosclerosis; 2024 Jul; 394():117236. PubMed ID: 37582673
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
    Amarenco P; Goldstein LB; Callahan A; Sillesen H; Hennerici MG; O'Neill BJ; Rudolph AE; Simunovic L; Zivin JA; Welch KM;
    Atherosclerosis; 2009 Jun; 204(2):515-20. PubMed ID: 18962621
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
    Rosenblit PD
    Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Attainment of lipid goals and long-term mortality after coronary-artery bypass surgery.
    Zafrir B; Saliba W; Jaffe R; Sliman H; Flugelman MY; Sharoni E
    Eur J Prev Cardiol; 2019 Mar; 26(4):401-408. PubMed ID: 30426772
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Surprises From Genetic Analyses of Lipid Risk Factors for Atherosclerosis.
    Musunuru K; Kathiresan S
    Circ Res; 2016 Feb; 118(4):579-85. PubMed ID: 26892959
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of dehydroepiandrosterone (DHEA) supplementation on the lipid profile: A systematic review and dose-response meta-analysis of randomized controlled trials.
    Qin Y; O Santos H; Khani V; Tan SC; Zhi Y
    Nutr Metab Cardiovasc Dis; 2020 Aug; 30(9):1465-1475. PubMed ID: 32675010
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Do we reach target lipid levels in diabetic and non-diabetic patients with previous myocardial infarction?].
    Aleksić E; Stamenković R; Lapcević M; Deljanin-Ilić M; Djordjević D; Tasić I
    Srp Arh Celok Lek; 2011; 139(1-2):30-6. PubMed ID: 21568080
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lipid Lowering Therapy, Low-Density Lipoprotein Level and Risk of Intracerebral Hemorrhage - A Meta-Analysis.
    Judge C; Ruttledge S; Costello M; Murphy R; Loughlin E; Alvarez-Iglesias A; Ferguson J; Gorey S; Nolan A; Canavan M; O'Halloran M; O'Donnell MJ
    J Stroke Cerebrovasc Dis; 2019 Jun; 28(6):1703-1709. PubMed ID: 30878368
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Triglyceride-rich lipoproteins and HDL: what do recent trials tell us?
    Stock J
    Atherosclerosis; 2013 Jun; 228(2):329-31. PubMed ID: 23623013
    [No Abstract]   [Full Text] [Related]  

  • 31. Prevalence of low high-density lipoprotein cholesterol and hypertriglyceridaemia in patients treated with hypolipidaemic drugs.
    Laforest L; Souchet T; Moulin P; Ritleng C; Desamericq G; Le Jeunne P; Schwalm MS; Van Ganse E
    Arch Cardiovasc Dis; 2009 Jan; 102(1):43-50. PubMed ID: 19233108
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis.
    Lee M; Saver JL; Towfighi A; Chow J; Ovbiagele B
    Atherosclerosis; 2011 Aug; 217(2):492-8. PubMed ID: 21592479
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases.
    Shinkai H
    Vasc Health Risk Manag; 2012; 8():323-31. PubMed ID: 22661899
    [TBL] [Abstract][Full Text] [Related]  

  • 34. On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin).
    Mora S; Glynn RJ; Boekholdt SM; Nordestgaard BG; Kastelein JJ; Ridker PM
    J Am Coll Cardiol; 2012 Apr; 59(17):1521-8. PubMed ID: 22516441
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.
    Rubins HB; Robins SJ; Collins D; Fye CL; Anderson JW; Elam MB; Faas FH; Linares E; Schaefer EJ; Schectman G; Wilt TJ; Wittes J
    N Engl J Med; 1999 Aug; 341(6):410-8. PubMed ID: 10438259
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Control of the overall lipid profile.
    Blasco M; Ascaso JF;
    Clin Investig Arterioscler; 2019 Dec; 31 Suppl 2():34-41. PubMed ID: 31785850
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Triglycerides: A reappraisal.
    Wiesner P; Watson KE
    Trends Cardiovasc Med; 2017 Aug; 27(6):428-432. PubMed ID: 28438398
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular Disease Risk Factor? New Insights From the Framingham Offspring Study.
    Bartlett J; Predazzi IM; Williams SM; Bush WS; Kim Y; Havas S; Toth PP; Fazio S; Miller M
    Circ Cardiovasc Qual Outcomes; 2016 May; 9(3):206-212. PubMed ID: 27166203
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control.
    Vallejo-Vaz AJ; Ray KK; Ginsberg HN; Davidson MH; Eckel RH; Lee LV; Bessac L; Pordy R; Letierce A; Cannon CP
    Atherosclerosis; 2019 Sep; 288():85-93. PubMed ID: 31349086
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use.
    Verma S; Leiter LA; Mazer CD; Bain SC; Buse J; Marso S; Nauck M; Zinman B; Bosch-Traberg H; Rasmussen S; Michelsen MM; Bhatt DL
    Circulation; 2018 Oct; 138(15):1605-1607. PubMed ID: 30354517
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.